Fig. 1. Effect of canagliflozin and puerarin on body weight and hyperglycemia.
(A) Body weight in control and diabetic mice with different treatments at the end of the 22nd week. (B) Blood glucose in control mice and diabetic mice with different treatments at the end of the 22nd week. (C) Body weight time course in control mice and diabetic mice with different treatments. (D) Blood glucose time course in control mice and diabetic mice with different treatments. Data are shown as mean ± SD (n = 6). #p < 0.05, ##p < 0.01 vs. control group; *p < 0.05, **p < 0.01 vs. diabetes group; ^p < 0.05, ^^p < 0.01 vs. canagliflozin group.
© Korean J Physiol Pharmacol
